Skip to main content

Table 1 Number of patients, demographic data and Charlson comorbidities at index

From: Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany

 

TNF inhibitor naive patients (n = 1,468)

TNF inhibitor continuing patients (n = 733)

TNF inhibitor total patients (n = 2,201)

 

Adalimumab (n = 669)

Etanercept (n = 628)

Infliximab (n = 171)

Adalimumab (n = 248)

Etanercept (n = 367)

Infliximab (n = 118)

Adalimumab (n = 917)

Etanercept (n = 995)

Infliximab (n = 289)

Mean age1

57

58

58

56

55

55

56

57

56

Female2, %

88

88

89

87

89

86

88

89

88

Charlson Comorbidities Index1,3

1.62

1.69

1.52

1.49

1.35

1.42

1.58

1.56

1.48

1. Myocardial infarction

1.08%

2.20%

0.61%

0.43%

0.91%

1.89%

0.91%

1.74%

1.11%

2. Congestive heart failure

4.62%

4.06%

3.05%

4.33%

3.66%

1.89%

4.54%

3.92%

2.59%

3. Peripheral vascular disease

4.00%

6.60%

4.88%

3.90%

3.96%

5.66%

3.97%

5.66%

5.19%

4. Cerebrovascular disease

4.46%

3.72%

2.44%

1.73%

2.74%

1.89%

3.75%

3.37%

2.22%

5. Dementia

0.46%

0.34%

0.00%

0.00%

0.00%

0.00%

0.34%

0.22%

0.00%

6. Chronic pulmonary disease

14.46%

14.38%

9.15%

19.91%

14.33%

11.32%

15.89%

14.36%

10.00%

7. Peptic ulcer disease

2.92%

2.20%

2.44%

2.60%

1.83%

5.66%

2.84%

2.07%

3.70%

8. Mild liver disease

9.54%

9.64%

8.54%

8.66%

4.88%

9.43%

9.31%

7.94%

8.89%

9. Diabetes without chronic complication

10.15%

13.54%

9.15%

9.96%

8.54%

9.43%

10.10%

11.75%

9.26%

10. Diabetes with chronic complication

2.31%

4.91%

3.05%

2.16%

2.13%

4.72%

2.27%

3.92%

3.70%

11. Hemiplegia or paraplegia

0.92%

0.68%

0.00%

0.43%

0.61%

0.00%

0.79%

0.65%

0.00%

12. Renal disease

3.85%

4.40%

5.49%

1.73%

4.57%

0.94%

3.29%

4.46%

3.70%

13. Any malignancy. including lymphoma and leukaemia. except malignant neoplasm of skin

2.46%

4.23%

3.05%

1.30%

1.83%

2.83%

2.16%

3.37%

2.96%

14. Moderate or severe liver disease

0.00%

0.00%

0.00%

0.00%

0.30%

0.00%

0.00%

0.11%

0.00%

15. Metastatic solid tumour

0.31%

0.17%

0.00%

0.00%

0.00%

0.00%

0.23%

0.11%

0.00%

16. AIDS/HIV

0.00%

0.17%

0.00%

0.43%

0.00%

0.00%

0.11%

0.11%

0.00%

 

F- and p-values

 

Mean age

Gender

Charlson index

Mean age

Gender

Charlson index

Mean age

Gender

Charlson index

Adalimumab vs. etanercept

2.6254

1.000

1.3998

1.679

0.957

2.205

0.7768

1.000

0.5637

Adalimumab vs. infliximab

1.5851

1.000

1.3518

1.455

1.000

0.803

0.1062

1.000

2.0666

Etanercept vs. infliximab

0.1165

1.000

2.2446

0.233

0.825

0.8645

0.4249

1.000

1.7001

 

Tukey-Kramer

Bonferroni

Tukey-Kramer

Tukey-Kramer

Bonferroni

Tukey-Kramer

Tukey-Kramer

Bonferroni

Tukey-Kramer